Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW: Elritercept in Transfusion-Dependent Anemia in MDS
NCT06499285Phase 3Recruiting
- Sponsor
- Takeda
- Start
- May 2025
- Primary completion
- Sep 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 26
01
Overview
A Phase 3 trial of elritercept in myelodysplastic syndrome (MDS), sponsored by Takeda. Started May 2025; status: recruiting.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06499285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06499285.